How many drugs treat Peptic ulcer?

Drug Landscape tracks 10 marketed treatments for Peptic ulcer (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/peptic-ulcer.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Peptic ulcer — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Peptic ulcer (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Peptic ulcer, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Dexilant	DEXLANSOPRAZOLE	Takeda	Proton Pump Inhibitor [EPC]	(H+, K+)-ATPase	2009-01-01
Nexium	esomeprazole	AstraZeneca	Proton pump inhibitor (PPI)	Potassium-transporting ATPase	2001-02-20
Protonix	pantoprazole	Generic (originally Byk Gulden/Altana/Nycomed)	Proton pump inhibitor (PPI)	ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1	2000-02-02
Pantoprazole Sodium	Pantoprazole Sodium	Pfizer	Proton pump inhibitor (PPI)	(H+, K+)-ATPase enzyme	2000-01-01
Aciphex	rabeprazole	Waylis	Proton Pump Inhibitor	Potassium-transporting ATPase	1999-01-01
Prevacid	lansoprazole	Generic (originally Takeda)	Proton pump inhibitor (PPI)	ATP-binding cassette sub-family G member 2, Cytochrome P450 2C19, Cytosolic endo-beta-N-acetylglucosaminidase	1995-05-10
Renacidin	MAGNESIUM CARBONATE	United Guardian	Vitamin C [EPC]		1990-01-01
Prilosec	omeprazole	AstraZeneca (originally Astra AB)	Proton pump inhibitor (PPI)	ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19	1989-09-14
Gaviscon	MAGNESIUM SILICATE	Sanofi	magnesium silicate		1983-01-01
Gaviscon	ALGELDRATE	Sanofi	algeldrate		1983-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 13 drugs in Peptic ulcer
Endo · 3 drugs in Peptic ulcer
Sanofi · 3 drugs in Peptic ulcer
Takeda · 2 drugs in Peptic ulcer
Chang Gung Memorial Hospital · 1 drug in Peptic ulcer
AstraZeneca (originally Astra AB) · 1 drug in Peptic ulcer
Bausch Health · 1 drug in Peptic ulcer
Generic (multiple manufacturers) · 1 drug in Peptic ulcer
Generic (originally Byk Gulden/Altana/Nycomed) · 1 drug in Peptic ulcer
Generic (originally Takeda) · 1 drug in Peptic ulcer
Genuine Research Center, Egypt · 1 drug in Peptic ulcer
GSK · 1 drug in Peptic ulcer

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Peptic ulcer:

Cite this brief

Drug Landscape (2026). Peptic ulcer — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/peptic-ulcer. Accessed 2026-06-10.

Peptic ulcer full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing